These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 20934437)

  • 1. Substance use and HIV disease progression in the HAART era: implications for the primary prevention of HIV.
    Carrico AW
    Life Sci; 2011 May; 88(21-22):940-7. PubMed ID: 20934437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential impact of drugs of abuse on mother-to-child transmission (MTCT) of HIV in the era of highly active antiretroviral therapy (HAART).
    Purohit V; Rapaka RS; Schnur P; Shurtleff D
    Life Sci; 2011 May; 88(21-22):909-16. PubMed ID: 21477599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.
    Bouhnik AD; Préau M; Vincent E; Carrieri MP; Gallais H; Lepeu G; Gastaut JA; Moatti JP; Spire B;
    Antivir Ther; 2005; 10(1):53-61. PubMed ID: 15751763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mother-to-child transmission of HIV-1 in the era prior to the availability of combination antiretroviral therapy: the role of drugs of abuse.
    Van Dyke RB
    Life Sci; 2011 May; 88(21-22):922-5. PubMed ID: 21439978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing treatment outcomes in HIV-infected patients with substance abuse issues.
    Celentano DD; Lucas G
    Clin Infect Dis; 2007 Dec; 45 Suppl 4():S318-23. PubMed ID: 18190306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver.
    Kerr T; Palepu A; Barness G; Walsh J; Hogg R; Montaner J; Tyndall M; Wood E
    Antivir Ther; 2004 Jun; 9(3):407-14. PubMed ID: 15259903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
    Wang C; Vlahov D; Galai N; Bareta J; Strathdee SA; Nelson KE; Sterling TR
    J Infect Dis; 2004 Sep; 190(6):1046-54. PubMed ID: 15319852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
    Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
    Wong KH; Chan KC; Lee SS
    Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease progression in HIV-1 infected children and adolescents--results of a German-Austrian cohort study.
    Funk MB; Buchholz B; Notheis G; Neubert J; Feiterna-Sperling C; Ganschow R; Simon T; Hornemann F; Peters AM; Rütschle H; Horneff G; Lechner E; Hanschmann KM; Wintergerst U;
    Eur J Med Res; 2008 Aug; 13(8):371-8. PubMed ID: 18952519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outpatient pharmacy care and HIV viral load response among patients on HAART.
    Castillo E; Palepu A; Beardsell A; Akagi L; Yip B; Montaner JS; Hogg RS
    AIDS Care; 2004 May; 16(4):446-57. PubMed ID: 15203413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy.
    Grau I; Pallares R; Tubau F; Schulze MH; Llopis F; Podzamczer D; Liñares J; Gudiol F;
    Arch Intern Med; 2005 Jul; 165(13):1533-40. PubMed ID: 16009870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombocytopenia in HIV-infected drug users in the HAART era.
    Burbano X; Miguez MJ; Lecusay R; Rodriguez A; Ruiz P; Morales G; Castillo G; Baum M; Shor-Posner G
    Platelets; 2001 Dec; 12(8):456-61. PubMed ID: 11798394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy.
    Lucas GM; Griswold M; Gebo KA; Keruly J; Chaisson RE; Moore RD
    Am J Epidemiol; 2006 Mar; 163(5):412-20. PubMed ID: 16394200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival in HIV-infected patients is associated with hepatitis C virus infection and injecting drug use since the use of highly active antiretroviral therapy in the Lyon observational database.
    Voirin N; Trépo C; Miailhes P; Touraine JL; Chidiac C; Peyramond D; Livrozet JM; Ritter J; Chevallier P; Fabry J; Allard R; Vanhems P
    J Viral Hepat; 2004 Nov; 11(6):559-62. PubMed ID: 15500557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Harmful alcohol consumption and patterns of substance use in HIV-infected patients receiving antiretrovirals (ANRS-EN12-VESPA Study): relevance for clinical management and intervention.
    Michel L; Carrieri MP; Fugon L; Roux P; Aubin HJ; Lert F; Obadia Y; Spire B;
    AIDS Care; 2010 Sep; 22(9):1136-45. PubMed ID: 20824566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early immunologic and virologic responses to highly active antiretroviral therapy and subsequent disease progression among HIV-infected injection drug users.
    Mehta SH; Lucas G; Astemborski J; Kirk GD; Vlahov D; Galai N
    AIDS Care; 2007 May; 19(5):637-45. PubMed ID: 17505924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy.
    Tai JH; Udoji MA; Barkanic G; Byrne DW; Rebeiro PF; Byram BR; Kheshti A; Carter JD; Graves CR; Raffanti SP; Sterling TR
    J Infect Dis; 2007 Oct; 196(7):1044-52. PubMed ID: 17763327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized clinical trial of community-based directly observed therapy as an adherence intervention for HAART among substance users.
    Macalino GE; Hogan JW; Mitty JA; Bazerman LB; Delong AK; Loewenthal H; Caliendo AM; Flanigan TP
    AIDS; 2007 Jul; 21(11):1473-7. PubMed ID: 17589194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.